CA3076115C - Thermo-kinetic mixing for pharmaceutical applications - Google Patents

Thermo-kinetic mixing for pharmaceutical applications Download PDF

Info

Publication number
CA3076115C
CA3076115C CA3076115A CA3076115A CA3076115C CA 3076115 C CA3076115 C CA 3076115C CA 3076115 A CA3076115 A CA 3076115A CA 3076115 A CA3076115 A CA 3076115A CA 3076115 C CA3076115 C CA 3076115C
Authority
CA
Canada
Prior art keywords
tkc
api
processed
processing
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3076115A
Other languages
English (en)
French (fr)
Other versions
CA3076115A1 (en
Inventor
Chris Brough
James W. Mcginity
Dave A. Miller
James C. Dinunzio
Robert O Williams, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Austinpx LLC
Original Assignee
University of Texas System
DisperSol Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, DisperSol Technologies LLC filed Critical University of Texas System
Publication of CA3076115A1 publication Critical patent/CA3076115A1/en
Application granted granted Critical
Publication of CA3076115C publication Critical patent/CA3076115C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3076115A 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications Active CA3076115C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95704407P 2007-08-21 2007-08-21
US60/957,044 2007-08-21
US5092208P 2008-05-06 2008-05-06
US60/050,922 2008-05-06
CA2990445A CA2990445C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2990445A Division CA2990445C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Publications (2)

Publication Number Publication Date
CA3076115A1 CA3076115A1 (en) 2009-02-26
CA3076115C true CA3076115C (en) 2022-06-28

Family

ID=40378995

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3076115A Active CA3076115C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications
CA2697099A Active CA2697099C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications
CA2990445A Active CA2990445C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2697099A Active CA2697099C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications
CA2990445A Active CA2990445C (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Country Status (6)

Country Link
US (6) US8486423B2 (https=)
EP (1) EP2187968A4 (https=)
JP (4) JP6073043B2 (https=)
CN (1) CN101835492B (https=)
CA (3) CA3076115C (https=)
WO (1) WO2009026461A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
WO2010068866A2 (en) * 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
US9821283B1 (en) * 2011-07-25 2017-11-21 Dispersol Technologies, Llc Direct probe sensed temperature method for speed change for heat sensitive portions of a thermokinetically melt blended batch
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
US20150182457A1 (en) * 2013-12-31 2015-07-02 Ascendia Pharmaceuticals, Llc Pharmaceutical Compositions For Poorly Water-Soluble Compounds
MA39734B1 (fr) 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体
DK3131667T3 (da) * 2014-04-18 2021-10-25 Dispersol Technologies Llc Flerhastigheds fremgangsmåde og blander til konservering af varmefølsomme portioner af et termokinetisk smelte blandet parti
WO2016073421A1 (en) * 2014-11-03 2016-05-12 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
CN107847490A (zh) * 2015-06-17 2018-03-27 分散技术有限责任公司 改进的地拉罗司制剂及制备其的方法
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017196712A1 (en) * 2016-05-09 2017-11-16 Dispersol Technologies, Llc Improved drug formulations
IL324523A (en) 2016-05-13 2026-01-01 Merck Patent Gmbh Polymer particle size and distribution for melt extrusion application
JP7376220B2 (ja) * 2017-09-11 2023-11-08 オースティンピーエックス リミテッド ライアビリティ カンパニー 熱動力学的に溶融ブレンドされるバッチの熱感受性部分用の、直接プローブにより感知した温度による、速度変更のための方法
MA50189A (fr) * 2017-09-22 2021-05-19 Dispersol Technologies Llc Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
ES2836192T3 (es) 2017-10-13 2021-06-24 Dispersol Technologies Llc Método de detección de la temperatura por sonda directa para determinar el cambio de velocidad para porciones sensibles al calor de un lote combinado fundido termocinéticamente
CN109663524B (zh) * 2017-10-13 2022-07-15 分散技术有限责任公司 用于热动力学熔体共混批次的热敏部分的速度改变的直接进样探头感测温度方法
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
EP3728543B1 (en) * 2017-12-21 2025-10-29 Danisco US Inc. Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
US12076328B2 (en) 2020-04-01 2024-09-03 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022125869A1 (en) * 2020-12-11 2022-06-16 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
AU2022250858A1 (en) * 2021-04-01 2023-11-16 Merck Patent Gmbh Process for continuous hot melt granulation of low soluble pharmaceuticals
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US20250000794A1 (en) * 2021-07-27 2025-01-02 Board Of Regents, The University Of Texas System Improved drug processing methods to increase drug loading
US20230112800A1 (en) 2021-08-31 2023-04-13 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119453203A (zh) * 2025-01-09 2025-02-18 山东百农思达生物科技有限公司 一种含杀虫单和阿维菌素的复合微乳制剂及其制备工艺

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319478A1 (fr) * 1975-07-30 1977-02-25 Gen Electric Extrudeuse et procede d'extrusion de materiaux thermoplastiques
US4230615A (en) * 1978-11-21 1980-10-28 Carlew Chemicals Limited Process for controlled mixing in a high intensity mixer
US4628073A (en) * 1984-10-03 1986-12-09 Monsanto Company Soft, rubbery, multiphase matrix material and methods for its production
US4789597A (en) * 1987-01-12 1988-12-06 Fetherstonhaugh & Co. Incorporation of chemically reactive agents on resin particles
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH07159587A (ja) 1993-12-07 1995-06-23 Hitachi Ltd 樹脂性能モニタ
JPH07187998A (ja) * 1993-12-27 1995-07-25 Kao Corp 錠剤の製造方法
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5895790A (en) * 1995-03-14 1999-04-20 Good; Elmer Thermosetting wide range polymer blends
DE19531067A1 (de) 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6709146B1 (en) * 2000-07-28 2004-03-23 David Little Thermokinetic mixer and method of using
EE200400034A (et) * 2001-06-22 2004-06-15 Pfizer Products Inc. Amorfse ravimaine adsorbaatide farmatseutilised kompositsioonid
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
JP4783278B2 (ja) 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
CA2546115C (en) * 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
US20050258288A1 (en) 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
JP2005263758A (ja) * 2004-03-22 2005-09-29 Kirin Brewery Co Ltd 非晶質のｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キナゾリニル）オキシ］フェニル｝−ｎ’−プロピルウレア
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
US20060264497A1 (en) 2005-03-28 2006-11-23 Zeligs Michael A Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
JP4429262B2 (ja) * 2005-12-09 2010-03-10 壽製薬株式会社 フェノフィブラートの固体分散体
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
JP2012047227A (ja) 2010-08-25 2012-03-08 Nippon Steel & Sumikin Metal Products Co Ltd ナット保持部材
US20140039031A1 (en) 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
WO2016073421A1 (en) 2014-11-03 2016-05-12 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same

Also Published As

Publication number Publication date
CN101835492B (zh) 2012-11-21
CA2990445A1 (en) 2009-02-26
EP2187968A2 (en) 2010-05-26
JP6073043B2 (ja) 2017-02-01
US8486423B2 (en) 2013-07-16
US10668085B2 (en) 2020-06-02
US10022385B2 (en) 2018-07-17
US9339440B2 (en) 2016-05-17
CA2697099A1 (en) 2009-02-26
US20090053315A1 (en) 2009-02-26
US12023343B2 (en) 2024-07-02
US20230172949A1 (en) 2023-06-08
CA3076115A1 (en) 2009-02-26
US20180360850A1 (en) 2018-12-20
JP2016121195A (ja) 2016-07-07
US20200261473A1 (en) 2020-08-20
JP2014221816A (ja) 2014-11-27
CA2697099C (en) 2018-02-20
CN101835492A (zh) 2010-09-15
EP2187968A4 (en) 2013-02-20
WO2009026461A3 (en) 2009-04-30
JP2010536877A (ja) 2010-12-02
US11439650B2 (en) 2022-09-13
US20160250230A1 (en) 2016-09-01
WO2009026461A2 (en) 2009-02-26
JP2019052173A (ja) 2019-04-04
CA2990445C (en) 2020-05-05
US20130303630A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
US12023343B2 (en) Thermo-kinetic mixing for pharmaceutical applications
JP6730315B2 (ja) 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体
JP2021059540A (ja) 非晶質薬物の固溶体を含む剤型（ｄｏｓａｇｅ ｆｏｒｍ ｉｎｃｏｒｐｏｒａｔｉｎｇ ａｎ ａｍｏｒｐｈｏｕｓ ｄｒｕｇ ｓｏｌｉｄ ｓｏｌｕｔｉｏｎ）
JP6491669B2 (ja) Ｃｇｒｐ活性化合物の錠剤製剤
KR20100134557A (ko) 고체 약제학적 투여 제형
US20240390285A1 (en) High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients
RU2619840C1 (ru) Фармацевтическая композиция для лечения ВИЧ-инфекции
EP4008314A2 (en) Thermo-kinetic mixing for pharmaceutical applications
Williams III et al. Thermo-kinetic mixing for pharmaceutical applications
US20230114357A1 (en) Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
McGinity et al. Brough et al.
DiNunzio et al. Melt extrusion: pharmaceutical applications
Alshetaili Solubility enhancement, mechanical properties and taste masking of poorly water soluble compounds by optimizing hot melt extrusion processing
Keen Novel formulations and thermal processes for bioavailability enhancement of soluble and poorly soluble drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250811

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828